HHS Cancels $766 Million Moderna Vaccine Contract Amid Safety Concerns
The U.S. cancels funding for Moderna's mRNA bird flu vaccine, citing safety issues, as H5N1 cases rise in the U.S.
Overview
The U.S. Department of Health and Human Services has canceled a $766 million contract with Moderna for an mRNA vaccine against H5N1 bird flu, citing safety concerns. Despite positive trial results showing a 44.5-fold increase in antibody levels, officials deemed further investment unjustifiable, emphasizing a shift towards established vaccine technologies. Critics warn this decision jeopardizes pandemic preparedness as H5N1 spreads among U.S. poultry and dairy cows, with 70 human cases reported. Health Secretary Robert F. Kennedy Jr. expressed skepticism about mRNA technology, claiming it remains under-tested, while Moderna seeks alternative funding to continue its vaccine development.
Content generated by AI—learn more or report issue.
Get both sides in 5 minutes with our daily newsletter.
Analysis
Left
There are not enough sources from this perspective to provide an analysis.
Center
The articles present a mix of neutral and negative tones regarding Moderna's vaccine funding cancellation.
Concerns about safety and efficacy testing are emphasized, alongside criticism of political figures and their actions.
Positive trial results are mentioned, but uncertainty about the vaccine's future remains a key theme.
Right
The articles express a negative tone about funding cuts for Moderna's mRNA bird flu vaccine.
Concerns are raised about the safety and efficacy of mRNA technology and the Biden administration's transparency.
The cancellation of funding is criticized as lacking scientific and ethical justification.
Left
There are not enough sources from this perspective to provide an analysis.
Center
The articles present a mix of neutral and negative tones regarding Moderna's vaccine funding cancellation.
Concerns about safety and efficacy testing are emphasized, alongside criticism of political figures and their actions.
Positive trial results are mentioned, but uncertainty about the vaccine's future remains a key theme.
Right
The articles express a negative tone about funding cuts for Moderna's mRNA bird flu vaccine.
Concerns are raised about the safety and efficacy of mRNA technology and the Biden administration's transparency.
The cancellation of funding is criticized as lacking scientific and ethical justification.
Articles (7)
CNN·19d·"…However, HHS said Wednesday that the project doesn’t meet scientific or safety expectations for continued investment."
NBC News·18d·"…The cancellation came as Moderna announced positive interim results from an early-stage trial of the vaccine that targeted H5 bird flu virus, tested in 300 healthy adults."
NPR·19d·"…The cancellation comes even though Moderna says a study involving 300 healthy adults had produced 'positive interim' results and the company 'had previously expected to advance the program to late-stage development.'"
ARS Technica·18d·"…The decision to cancel the funding—which would support thorough safety and efficacy testing of the vaccines—was because the vaccines needed more testing."
Boston Herald·19d·"…The cancelation came as Moderna announced positive interim results from an early-stage trial of the vaccine that targeted H5 bird flu virus, tested in 300 healthy adults."
Washington Examiner·18d·"…Concerns have since been raised that negative side effects of the COVID-19 mRNA vaccines, including risks of myocarditis, were deliberately downplayed to the public as Biden health officials pushed for expanded vaccination rates during the pandemic."
Epoch Times·18d·"…The Department of Health and Human Services (HHS) has canceled funding for Moderna’s vaccine against avian influenza, also known as the bird flu, the department confirmed on May 29."
FAQ
History
- 19d3 articles